SCHEMBL3457246

SCHEMBL3457246

Cc1c(S(C)(=O)=O)oc2ccccc2c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 10/20 0.52
KDM4E B2RXH2 5/20 0.52
HPGD P15428 2/20 0.52
ALDH1A1 P00352 2/20 0.52
GLA P06280 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAPT P10636 1/20 0.52
PGAM1 P18669 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HSD17B10 Q99714 1/20 0.52
AKR1B1 P15121 1/20 0.46
NTRK1 P04629 1/20 0.42
PLK3 Q9H4B4 1/20 0.42
THRB P10828 1/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 1/20 0.42
RET P07949 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8713236 0.77 CYP3A4 (0.43) MAOAKDM4EHPGDALDH1A1GLA
SCHEMBL6719113 0.76 MAOA (0.61) MAOAKDM4EHPGDALDH1A1GLA
3-Methyl-2-Phenyl-4H-Chromen-4-One SCHEMBL694139 0.74 ALDH1A1 (0.68) MAOAKDM4EHPGDALDH1A1GLA
SCHEMBL5675916 0.73 MAOA (0.57) MAOAKDM4EHPGDALDH1A1GLA
SCHEMBL10216424 0.73 KDM4E (0.58) MAOAKDM4EHPGDALDH1A1GLA
SCHEMBL3456533 0.73 MAOA (0.57) MAOAKDM4EHPGDALDH1A1GLA
SCHEMBL3456661 0.71 MAOA (0.55) MAOAKDM4EHPGDALDH1A1GLA
SCHEMBL15880721 0.71 AKR1B1 (0.51) MAOAKDM4EHPGDALDH1A1GLA
SCHEMBL8607746 0.71 TSHR (0.72) MAOAKDM4EHPGDALDH1A1GLA
SCHEMBL31217585 0.70 CYP2C9 (0.55) MAOAKDM4EHPGDALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253333-B1 Contrast Agents for Myocardial Perfusion Imaging LANTHEUS MEDICAL IMAGING INC (US) 2019-06-12 EP disclosed
EP-2253333-B1 Contrast Agents for Myocardial Perfusion Imaging LANTHEUS MEDICAL IMAGING INC (US) 2019-06-12 EP disclosed
CN-101843908-B Contrast agents for myocardial perfusion imaging BRISTOL MYERS SQUIBB PHARMA CO 2014-09-10 CN disclosed
US-20130028837-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING LANTHEUS MEDICAL IMAGING, INC. (US) 2013-01-31 US disclosed
US-20130028837-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING LANTHEUS MEDICAL IMAGING, INC. (US) 2013-01-31 US disclosed
US-20130028837-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING LANTHEUS MEDICAL IMAGING, INC. (US) 2013-01-31 US disclosed
US-8263042-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING, INC. (US) 2012-09-11 US disclosed
US-8263042-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING, INC. (US) 2012-09-11 US disclosed
US-8263042-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING, INC. (US) 2012-09-11 US disclosed
EP-2253333-A2 Contrast Agents for Myocardial Perfusion Imaging Lantheus Medical Imaging, Inc. (US) 2010-11-24 EP disclosed
EP-1740225-A4 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING BRISTOL MYERS SQUIBB CO (US) 2009-08-19 EP disclosed
US-20090104118-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING CITIZENS BANK, N.A. 2009-04-23 US disclosed
US-20090104118-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING CITIZENS BANK, N.A. 2009-04-23 US disclosed
US-20090104118-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING CITIZENS BANK, N.A. 2009-04-23 US disclosed
US-7485283-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING (US) 2009-02-03 US disclosed
US-7485283-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING (US) 2009-02-03 US disclosed
US-7485283-B2 Contrast agents for myocardial perfusion imaging LANTHEUS MEDICAL IMAGING (US) 2009-02-03 US disclosed
EP-1740225-A2 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING Bristol-Myers Squibb Company (US) 2007-01-10 EP disclosed
WO-2005105159-A2 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-11-10 WO disclosed
US-20050244332-A1 Contrast agents for myocardial perfusion imaging CITIZENS BANK, N.A. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090104118-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING TNNI3, TNNT2, FABP3 MAOA 1888/4885KDM4E 4486/4885HPGD 2447/4885
US-20050244332-A1 Contrast agents for myocardial perfusion imaging TNNI3, TNNT2, FABP3 MAOA 1888/4885KDM4E 4486/4885HPGD 2447/4885
US-20130028837-A1 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING TNNI3, TNNT2, FABP3 MAOA 1888/4885KDM4E 4486/4885HPGD 2447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.